Panelists discuss how acute myeloid leukemia treatment has evolved from a one-size-fits-all approach to personalized medicine incorporating genetic profiling, targeted therapies like venetoclax and IDH inhibitors, emerging oral regimens, and comprehensive patient assessments that consider not only traditional fitness criteria but also social determinants of health, quality of life factors, and the potential for curative versus palliative care in different patient populations.
EP. 1: Overview of Pathophysiology of and Progression of AML
Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the hematopoietic stem cell level, with treatment decisions now increasingly integrated with specific genetic mutations despite the disease’s rapid progression timeline.
Watch
EP. 2: Risk Classification Systems in AML
Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, categorize patients based on complex cytogenetics and molecular features to guide prognosis and treatment selection.
Watch
EP. 3: Key Patient Factors to Consider in AML Treatment Decisions
Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while questioning whether intensive therapy should automatically be given to fit patients given newer effective treatment options.
Watch
EP. 4: Provider Perspectives on Biggest Unmet Needs in AML Care
Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, managing the increasingly older population with secondary mutations, and ensuring global access to targeted therapies and next-generation sequencing.
Watch
EP. 5: Social Determinants to AML Treatment Approach
Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring frequent clinic visits for blood work and transfusions, which disproportionately affects patients living far from treatment centers.
Watch
EP. 6: Latest NCCN Guidelines on the Standard of Care for Patients With AML
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs nonintensive therapy eligibility and specific genetic mutations like FLT3, IDH1, and TP53.
Watch
EP. 7: Patient Eligibility for Transplant, Induction, and Consolidation in AML Treatment
Panelists discuss how transplant eligibility has expanded beyond traditional intensive chemotherapy candidates to include patients receiving lower intensity regimens, with earlier transplant consultations and consideration of organ function preservation through less toxic induction approaches.
Watch
EP. 8: Venetoclax and the Impact on Management of Older Patients With AML
Panelists discuss how venetoclax has revolutionized AML treatment by providing effective therapy options for older patients with previously untreatable disease, enabling higher response rates, longer survival, and increased transplant eligibility while transforming the treatment landscape across all age groups.
Watch